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A B S T R A C T
Background
Bronchiectasis is a major contributor to chronic respiratory morbidity and mortality worldwide. Wheeze and other asthma-like symp-
toms and bronchial hyperreactivity may occur in people with bronchiectasis. Physicians often use asthma treatments in patients with
bronchiectasis.
Objectives
To assess the effects of inhaled long-acting beta2-agonists (LABA) combined with inhaled corticosteroids (ICS) in children and adults
with bronchiectasis during (1) acute exacerbations and (2) stable state.
Search methods
TheCochrane Airways Group searched the the Cochrane Airways Group Specialised Register of Trials, which includes records identified
from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and other databases. The Cochrane
Airways Group performed the latest searches in October 2013.
Selection criteria
All randomised controlled trials (RCTs) of combined ICS and LABA compared with a control (placebo, no treatment, ICS as monother-
apy) in children and adults with bronchiectasis not related to cystic fibrosis (CF).
Data collection and analysis
Two review authors extracted data independently using standardmethodological procedures as expected byTheCochraneCollaboration.
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Main results
We found no RCTs comparing ICS and LABA combination with either placebo or usual care. We included one RCT that compared
combined ICS and LABA with high-dose ICS in 40 adults with non-CF bronchiectasis without co-existent asthma. All participants
received three months of high-dose budesonide dipropionate treatment (1600 micrograms). After three months, participants were
randomly assigned to receive either high-dose budesonide dipropionate (1600 micrograms per day) or a combination of budesonide
with formoterol (640 micrograms of budesonide and 18 micrograms of formoterol) for three months. The study was not blinded.
We assessed it to be an RCT with overall high risk of bias. Data analysed in this review showed that those who received combined
ICS-LABA (in stable state) had a significantly better transition dyspnoea index (mean difference (MD) 1.29, 95% confidence interval
(CI) 0.40 to 2.18) and cough-free days (MD 12.30, 95% CI 2.38 to 22.2) compared with those receiving ICS after three months
of treatment. No significant difference was noted between groups in quality of life (MD -4.57, 95% CI -12.38 to 3.24), number of
hospitalisations (odds ratio (OR) 0.26, 95% CI 0.02 to 2.79) or lung function (forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC)). Investigators reported 37 adverse events in the ICS group versus 12 events in the ICS-LABA group but
did not mention the number of individuals experiencing adverse events. Hence differences between groups were not included in the
analyses. We assessed the overall evidence to be low quality.
Authors’ conclusions
In adults with bronchiectasis without co-existent asthma, during stable state, a small single trial with a high risk of bias suggests that
combined ICS-LABAmay improve dyspnoea and increase cough-free days in comparison with high-dose ICS. No data are provided for
or against, the use of combined ICS-LABA in adults with bronchiectasis during an acute exacerbation, or in children with bronchiectasis
in a stable or acute state. The absence of high quality evidencemeans that decisions to use or discontinue combined ICS-LABA in people
with bronchiectasis may need to take account of the presence or absence of co-existing airway hyper-responsiveness and consideration
of adverse events associated with combined
ICS-LABA.
P L A I N L A N G U A G E S U M M A R Y
Combined ICS-LABA for children and adults with bronchiectasis
A paucity of evidence is available to allow conclusions on whether combined inhaled corticosteroids (ICS)-long-acting beta2-agonists
(LABA) are equivalent or superior to placebo or ICS monotherapy for the treatment of stable or exacerbation (flare-up) state bronchiec-
tasis (Appendix 2).
Review question: Is any evidence available to show that combined ICS-LABA is superior to placebo or ICS monotherapy for the
treatment of stable or exacerbation state bronchiectasis in children and adults?
Study characteristics: A small, single-centre, non-blinded study that compared inhaled ICS-LABA with high-dose ICS.
Key results: A single study showed some benefit of the inhaled ICS-LABA combination over high-dose ICS in terms of indices of
clinical stability such as dyspnoea (shortness of breath), cough-free days and number of exacerbations but failed to show significant
improvement in lung function or microbiology. No data are available on children with bronchiectasis or adults with bronchiectasis
during an exacerbation phase. Until further evidence becomes available, we recommend that use of combined ICS-LABA should be
individualised according to the presence or likelihood of co-existing asthma features and risks of medications.
Quality of the evidence: This review is based on a single study, hence the quality of evidence is substantially limited.
Bottom line: The decision to use combined ICS-LABA in bronchiectasis must be made for individual patients on the basis of the
presence or absence of bronchial hyperreactivity, until further randomised controlled trials are conducted to answer this important
question.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Combination inhaled budesonide with formoterol (corticosteroids and long-acting beta2-agonists) compared with high-dose budesonide for bronchiectasis
Patient or population: 18 to 80 years of age with bronchiectasis
Settings: community
Intervention: medium-dose budesonide with formoterol (ICS-LABA)
Comparison: high-dose budesonide (ICS)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ICS ICS and LABA
SGRQ
Scores range from 0 to
100, with higher scores
indicating more limita-
tions
Follow-up: 3 months
Mean score 0.73 points
lower than baseline
Mean score in the ICS-
LABA groups was 4.57
lower than that in the ICS
groups (12.38 lower to 3.
24 higher)
MD -4.57 (-12.38 to 3.
24)
40 (1 study) ⊕⊕©©
low
The difference between
groups for change in
SGRQwasnot significant.
Quality of evidence was
downgraded for impreci-
sion and risk of bias
TDI
Total scores range from
- 9 to +9. The lower the
score, the greater the de-
terioration in severity of
dyspnoea, MCID ≥ 1
Follow-up: 3 months
Mean score 0.1 point
higher than baseline
1.29 higher (0.40 to 2.18
higher)
MD 1.29 (0.40 to 2.18) 40 (1 study) ⊕⊕©©
low
No significant difference
between groups. Quality
of evidence was down-
graded for imprecision
and risk of bias
Cough-free days
Percentage of days free
of cough
Follow-up: 3 months
3 per 100 12.30 per 100 higher (2.
38% to 22.22% more)
MD 12.30 (2.38 to 22.22) 40 (1 study) ⊕⊕©©
low
The difference is signifi-
cant but is based on only
1 study. Quality of evi-
dence was downgraded
for imprecision and risk
of bias
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Hospitalisations, num-
ber of participants with
1 or more exacerbations
Follow-up: 3 months
167 per 1000 49 per 1000 (4 to 358) OR 0.26 (0.02 to 2.79) 38 (1 study) ⊕⊕©©
low
These results should be
interpreted with caution,
as data are based on a
single study with a high
risk of bias. CI for com-
parative risk could not be
calculated. Quality of ev-
idence was downgraded
for imprecision and risk
of bias
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). As only one study was included in the review, assumed risk is not expressed as a range.
CI: confidence interval; ICS: Inhlaed corticosteroids (budesonide); LABA: long-acting beta2-agonists; MCID: minimal clinically important difference; OR: odds ratio; SGRQ: St George’s
Respiratory Questionnaire; TDI: transition dyspnoea index.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
These results come from a single study with a small number of participants and require confirmation in other, larger studies.
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B A C K G R O U N D
Although bronchiectasis is regarded in affluent countries as an
’orphan disease,’ it remains a major contributor to chronic respi-
ratory morbidity (Santamaria 2009; Seitz 2010; Weycker 2005)
and mortality (Roberts 2010) worldwide. Recent studies have re-
ported increased prevalence and hospitalisation due to bronchiec-
tasis over the past two decades (Santamaria 2009; Seitz 2010;
Weycker 2005). Estimated prevalence rates in the USA, based on a
retrospective cohort study, ranged from 4.2 cases per 100,000 per-
sons aged 18 to 34 years to 271.8 per 100,000 among those aged
over 75 years (Weycker 2005). The prevalence of bronchiectasis
is particularly high in some populations, such as among indige-
nous Australian children (1470 per 100,000) (Chang 2003) and
AlaskanNative children in theUSA (1600per 100,000) (Singleton
2000). Indeed, non-cystic fibrosis (CF) bronchiectasis is far more
common globally than CF bronchiectasis in both developing and
affluent countries (Chang 2011).
Description of the condition
Bronchiectasis, defined as abnormal widening of the bronchi with
airway suppuration, is a heterogeneous condition (King 2006).
People with bronchiectasis typically have prolonged and/or recur-
rent periods of wet or productive cough, with or without features
such as haemoptysis, chest pain, exertional dyspnoea, wheeze and
asthma-like symptoms, fatigue, recurrent chest infection, growth
failure, digital clubbing, hyperinflation and chest wall deformity
(Chang 2003; King 2006).
The underlying aetiology of bronchiectasis varies from recurrent
respiratory infections to rare immune deficiencies. Other causes
include primary ciliary dyskinesia, allergic bronchopulmonary as-
pergillosis and mycobacterial infection. However, bronchiecta-
sis is a common pathway for a variety of diseases. Thus, the
presence of bronchiectasis is increasingly recognised in common
respiratory diseases (e.g. chronic obstructive pulmonary disease
(COPD) (Keistinen 1997), asthma (Gupta 2009)), uncommon
diseases (e.g. bronchiolitis obliterans, sarcoidosis) and non-pri-
mary respiratory (e.g. autoimmune) diseases (Chang 2010).When
bronchiectasis is present along with another underlying disorder,
the morbidity and mortality of the underlying diseases are in-
creased (Keistinen 1997; Lewis 2002). For example, in diseases
like COPD, the presence of bronchiectasis has been reported in
29% to 50% (O’Brien 2000; Patel 2004) of cohorts and, when
present, increases the severity (Patel 2004) and frequency (Gursel
2006) of respiratory exacerbations.
Description of the intervention
Different types of long-acting beta2-agonists (LABA) (e.g. salme-
terol, formoterol) are available. New ultra-LABA (e.g. indacaterol,
olodaterol) are emerging. These LABA medications are available
through a variety of delivery systems (i.e. metered-dose inhalers
and various types of dry powder inhalers). Likewise, different types
of inhaled corticosteroids (ICS) (e.g. fluticasone, budesonide, ci-
clesonide, mometasone) and various methods of delivery are avail-
able. LABA with ICS can be delivered via separate inhalers or via
a single inhaler as combined therapy. Both delivery types will be
included in this review.
How the intervention might work
Asthma-like symptoms and airway hyperresponsiveness may oc-
cur in people with bronchiectasis (Chang 2010). When they
are present, this disorder may be associated with accelerated
pulmonary decline when compared with bronchiectasis without
asthma-like symptoms (Keistinen 1997; King 2005). Thus, medi-
cations beneficial for people with asthma, such as combined LABA
with ICS (Ducharme 2010), may also be beneficial for those with
bronchiectasis.
Inhaled beta2-agonists induce bronchodilation by acting on air-
way smooth muscle beta2-adrenoceptors (Walker 2011). LABA
have a duration of action of approximately 12 hours, in contrast
to short-acting beta2-agonists (SABA), which have a duration of
four to six hours. LABA are available in single inhalers (i.e. used
as monotherapy) or in combination with ICS (Cazzola 2011).
Cochrane reviews on SABA (Franco 2003) and LABA used as
monotherapy for people with bronchiectasis (Sheikh 2001) found
no eligible studies.
ICS may be beneficial in people with bronchiectasis by impacting
the inflammatory pathway. However, the Cochrane review on ICS
for people with bronchiectasis (Kapur 2009) that described six
studies in adults and no paediatric data found no significant dif-
ference between those who received ICS and those given placebo
for all outcomes examined (spirometry, clinical outcomes of exac-
erbation or sputum volume) when only placebo-controlled studies
were included (Kapur 2009).
LABA and ICS as individual monotherapy may have separate ben-
eficial effects in the management of people with bronchiectasis
during acute (exacerbation) and/or stable states. Thus, combining
LABA and ICS therapy may confer additional benefits. This may
be related to ICS negating the proinflammatory effects of long-
term beta2-adrenoceptor exposure (Cazzola 2011).
In COPD, LABA combined with ICS (compared with ICS alone)
reduces morbidity and mortality (Nannini 2013). In adults with
asthma, the addition of LABA to ICS reduces the exacerbation
rate and improves lung function (Ducharme 2010). Thus LABA
combined with ICS may also be beneficial in children and adults
with bronchiectasis.
Why it is important to do this review
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As asthma-like symptoms and airway hyperresponsiveness may
occur in people with bronchiectasis, asthma medications such as
beta2-agonists and ICS as monotherapy or combined therapy are
often used. Although asthmamay co-exist with bronchiectasis, au-
dible wheezemay reflect small airway obstruction related to airway
oedema and secretions rather than bronchospasm. A history of
use of asthma medication has been associated with both increased
(King 2005) or reduced rate of decline in forced expiratory volume
in one second (FEV1) (Twiss 2006). As described above, LABA
combined with ICS may confer additional clinical benefit over
either medication alone. Thus, a systematic review of the benefits,
or otherwise, of using LABA combined with ICS in people with
bronchiectasis will be useful in guiding clinical practice.
O B J E C T I V E S
To assess the effects of inhaled long-acting beta2-agonists (LABA)
combined with inhaled corticosteroids (ICS) in children and
adults with bronchiectasis during (1) acute exacerbations and (2)
stable state.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised controlled trials for inclusion in
this review. Long-term cross-over trials are contentious for the tar-
get population, as recent data have shown that bronchiectasis in
adults is generally a progressive condition. Nevertheless, to main-
tain consistency with the Cochrane review on ICS for bronchiec-
tasis (Kapur 2009), we also included cross-over studies.
Types of participants
Children or adults with bronchiectasis (defined clinically or radi-
ologically) not related to cystic fibrosis.
We planned to exclude participants with other diseases in which
bronchiectasis is not present, such as participants with asthma and
COPD who do not have co-existent bronchiectasis.
Types of interventions
All types of combined ICS and LABA compared with a control
(placebo, no treatment, ICS as monotherapy). ICS and LABA can
be delivered through separate inhalers or by a combined inhaler.
Types of outcome measures
Primary outcomes
1. For acute exacerbations.
i) Mean difference in symptom scores at end of trial.
ii) Duration of exacerbation.
2. For stable state.
i) Clinical indices of bronchiectasis control (quality of
life (QOL), Likert scale, visual analogue scale, level of
interference of cough, etc).
ii) Exacerbation frequency.
Secondary outcomes
1. For acute exacerbations.
i) Proportion of participants requiring hospitalisation
and total number of hospitalised days.
ii) Mean difference in other objective indices (airway
markers of inflammation, exhaled nitric oxide, etc).
iii) Mean difference in lung function indices (spirometry,
other lung volumes, airway hyperresponsiveness).
iv) Proportion of participants experiencing adverse effects
of the intervention (e.g. pharyngeal candidiasis, voice change).
2. For stable bronchiectasis.
i) Mortality.
ii) Radiology scores (high-resolution computed
tomography scans or chest radiographs).
iii) Lung function.
iv) Relevant airway markers of inflammation.
v) Proportion experiencing adverse effects of the
intervention (e.g. adrenal insufficiency, cataracts, linear growth).
Search methods for identification of studies
Electronic searches
The search was performed by the Cochrane Airways Group.
We identified trials from the Cochrane Airways Group Spe-
cialised Register of trials (CAGR), which is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL), part of The
Cochrane LIbrary, as well as MEDLINE, EMBASE, CINAHL,
AMED and PsycINFO, and from handsearching of respiratory
journals and meeting abstracts (see Appendix 1 for further details)
and records in the CAGR coded as ’bronchiectasis’ using the fol-
lowing terms:
(steroid* or corticosteroid or ICS or fluticasone or budesonide
or beclomet* or flunisolide or mometasone or ciclesonide) AND
(LABA or beta* or long-acting* or “long acting*” or *formoterol
or salmeterol or indacaterol or olodacaterol)
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We also conducted a search of ClinicalTrials.gov and the World
Health Organization (WHO) trial portal using appropriate key-
words. We searched all databases from their inception up to Oc-
tober 2013 with no restriction on language of publication or pub-
lication status.
Searching other resources
We checked the reference lists of all relevant primary studies and
review articles for additional references.We contacted the primary
author of the identified trial.
Data collection and analysis
Selection of studies
Both review authors independently assessed titles and abstracts
of studies identified by the search to identify potentially relevant
studies. For appropriate articles, we assigned each reference to a
study identifier and assessed the full text against the inclusion
criteria of this protocol. There was no disagreement between the
review authors on selection of studies.
Data extraction and management
We extracted data onto a data collection form. We discussed and
resolved discrepancies in the data. We transferred data from the
data collection form into Review Manager 5.1 (RevMan Version
5.1) and managed it according to recommendations provided in
the Cochrane Handbook for Systematic Review of Interventions (
Higgins 2011).
We extracted information from the single identified study for the
following characteristics.
1. Design (design, total duration of study and run-in, number
of study centres and locations, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, bronchiectasis
severity, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler
type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and
collected, time points reported).
Assessment of risk of bias in included studies
Both review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).We assessed the
risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each bias domain as high, low or unclear for each study.
Measures of treatment effect
For dichotomous variables, we calculated individual and pooled
statistics as odds ratios (ORs) with 95% confidence intervals (CIs).
For continuous outcomes measured on the same metrics, we cal-
culated individual and pooled statistics as mean differences (MDs)
with 95% CIs. For continuous outcomes measured on different
metrics, we planned to combine data using standardised mean dif-
ferences (SMDs).
For cross-over studies, we planned to include only the first arm
and to calculate mean treatment differences from raw data, with
variances extracted or imputed and entered as fixed-effect generic
inverse variance (GIV) outcomes, to provide summary weighted
differences and 95% CIs.
Unit of analysis issues
The unit of analysis was the participant. In cross-over trials, be-
cause there might be a carry-over effect from both ICS and LABA,
we planned that only data from the first arm would be included
in the meta-analysis when the data are combined with those from
parallel studies, as was previously done (Kapur 2009).
Dealing with missing data
We planned to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical out-
come data when possible. We planned to conduct intention-to-
treat (ITT) analysis by assuming that missing values would have
had poor outcomes. The single study included had analysed data
using ITT analysis.
Assessment of heterogeneity
We had planned to use the I2 statistic to measure heterogene-
ity among the trials in each analysis. As only one eligible study
was identified, assessment of heterogeneity was not applicable.
If we had identified substantial heterogeneity, we planned to ex-
plore this through prespecified subgroup analysis (see Subgroup
analysis and investigation of heterogeneity). We would have con-
sidered levels of heterogeneity greater than 50% as substantial.
Assessment of reporting biases
We planned to attempt to contact study authors and ask them to
provide missing outcome data in cases of suspected reporting bias.
When this was not possible, and the missing data were thought to
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introduce serious bias, we planned to explore the impact of includ-
ing such studies in the overall assessment of results by conducting
a sensitivity analysis.Weplanned to investigate publication bias by
visually inspecting a funnel plot if at least 10 trials were included
in a meta-analysis for a single outcome. As the review is based on
a single study, we have not done a funnel plot of studies.
Data synthesis
We analysed data using Review Manager 5 (RevMan Version
5.1), with a view toward using a fixed-effect MD (calculated as
a weighted MD) for continuous data variables. For dichotomous
outcome variables of each individual study, we calculated the ORs
using a modified ITT analysis (i.e. failure assumed if participant
drops out of study). This analysis assumes that participants not
available for outcome assessment have not improved (andprobably
represents a conservative estimate of effect).
We intended to calculate a number needed to treat (for an addi-
tional beneficial or harmful outcome) when possible for the differ-
ent levels of risk as represented by control group event rates over
a specified time period using the pooled OR, and its CI using an
online calculator, Visual Rx (Cates 2003).We constructed a ’Sum-
mary of findings’ table according to recommendations provided
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011)
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses on the
primary outcomes of both exacerbation and stable states.
1. Children versus adults.
2. Type of ICS-LABA combination.
3. Type of control arm (placebo/no treatment/ICS).
As only one included study was identified, subgroup analysis was
not possible.
Sensitivity analysis
Weplanned to assess the impact of the following important factors
on overall outcomes.
1. Study quality.
2. Variation in inclusion criteria.
3. Differences in medications used in the intervention and
comparison groups.
4. Differences in outcome measures.
5. Analysis using random-effects model.
6. Analysis by “treatment received” and analysis by “intention-
to-treat.”
We planned to remove from the meta-analysis studies considered
to be at high or unclear risk of bias for methodological quality
(as per the risk of bias table), and to examine any changes in the
summary statistics. As only one study was eligible for inclusion in
the review, sensitivity analysis was not undertaken.
Summary of findings table
We created a ’Summary of findings’ table using the methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011) and by using GRADEpro software. We included only the
primary outcomes and one secondary outcome.
R E S U L T S
Description of studies
Results of the search
The Airways Group search identified 51 potentially relevant titles
(Figure 1). Two review authors (VG and AC) independently as-
sessed the abstracts and retrieved three papers. Of these,only one
study fulfilled the study eligibility criteria (Included studies), and
the other two studies were excluded (Excluded studies). No paedi-
atric studies were identified. No studies were identified that com-
pared ICS-LABA versus placebo or usual care.
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Figure 1. Study flow diagram.
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Included studies
The single included study (Martinez-Garcia 2012) was conducted
in Spain in 40 adults between 18 and 80 years of age with non-
CF bronchiectasis. The study excluded patients with co-existent
asthma. The study authors reported it as a double-blinded, par-
allel-group RCT comparing high-dose budesonide dipropionate
treatment versus the combination of budesonide with formoterol.
However, on writing to the primary author, we were informed that
participants were aware of the different coloured turbuhalers. The
trial was carried out in two stages. During the first stage, all par-
ticipants received three months of high-dose budesonide dipro-
pionate treatment (1600 micrograms). All other non-study drugs
and steroids were stopped. After three months, participants were
randomly assigned to receive either high-dose budesonide dipro-
pionate (1600 micrograms per day) or a combination of budes-
onide with formoterol (640 micrograms of budesonide and 18
micrograms of formoterol) for three months. Bronchiectasis exac-
erbation was defined as subjective and persistent (24 hours) dete-
rioration in at least three respiratory symptoms, including cough,
dyspnoea, haemoptysis, increased sputum purulence or volume,
chest pain (with or without fever), radiographic deterioration, sys-
temic disturbances or changes in chest auscultation (Tsang 1998).
Outcomes for this study were health-related quality of life (as mea-
sured by St George’s Respiratory Questionnaire), transition dys-
pnoea index, cough-free days, rescue beta2-agonist inhalation as
needed, change in lung function, microbiology data, number of
exacerbations and adverse effects of the medications.
Excluded studies
We found two additional studies that were excluded, as they did
not fulfil the inclusion criteria (see Characteristics of excluded
studies). The first study (Mostafapour 2009) was published in
Croatian. Investigators reported significant improvement in lung
function parameters among 12 participants enrolled in the study,
all of whom received a combination of salmeterol and fluticasone.
This study was excluded because it was not an RCT. The second
study, published in Chinese (Ding 2006), used SABA. Investiga-
tors reported that those receiving combined ICS-SABA had a re-
duced quantity of sputum and fewer hospitalised days compared
with those given SABA alone or no therapy. Although this was
an RCT, the study was excluded because the inclusion criteria re-
quired LABA, not SABA.
Risk of bias in included studies
Overall we assessed the sole included study (Martinez-Garcia
2012) to be at high risk of bias, as detailed in the ’Risk of bias’
table and summarised in Figure 2.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Allocation
Participants were randomly assigned using a computer-generated
programme, but the details were not provided. Drugs were dis-
pensed by an independent pharmacist, but details of this were not
provided in the paper.
Blinding
This studywas described as double-blind. The two groups received
drugs in a similar regimen (i.e. two puffs two times a day). We
contacted the original study authors, who suggested that the two
inhalers did not look similar and hence did not fulfil the criteria
for adequate blinding.
Incomplete outcome data
The number of participants withdrawn because of adverse effects
(two in the high-dose budesonide group and one lost to follow-
up in the combination group) was reported, and ITT analysis was
used; therefore we judged the trial to be at low risk of attrition
bias.
Selective reporting
It was not suggested that selective reporting had occurred.
Other potential sources of bias
The study was sponsored by pharmaceutical companies, but the
study authors reported that the company had no role in the design
of the study, in collection and analysis of the data, or in preparation
of the manuscript.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
The included study was conducted during stable state. Thus, only
outcomes related to ’stable state’ are described below.
Clinical indices of bronchiectasis control: quality of life and
dyspnoea
Using the Spanish version of St George’s Respiratory Question-
naire (SGRQ),Martinez-Garcia 2012 and colleagues in their paper
reported significant improvement (5.3 point reduction in SGRQ
score) among participants using combined ICS and LABA but no
improvement in the ICS group (0.73 points). SGRQ score ranges
from 0 to 100, with higher scores indicating more severe limita-
tions. Data on differences between the groups were not mentioned
in the paper. The standard deviation (SD) for mean change in the
ICS-LABA group was calculated from the P value provided in the
paper. As no numbers were provided for the ICS group (controls),
we requested data from the study authors, who reported that the
change in the ICS group was 0.73 points. Because the P value was
not provided for the ICS group, we assumed the SD to be the
same as that in LABA-ICS group. No significant differences be-
tween groups were reported (MD -4.57, 95% CI -12.38 to 3.24;
Analysis 1.1, Figure 3) for SGRQ.
Figure 3. Forest plot of comparison: quality of life (total SGRQ score).
For the outcome of transition dyspnoea index, those receiving
combined ICS-LABA were significantly better than the ICS group
(MD 1.29, 95% CI 0.40 to 2.18; Analysis 1.2, Figure 4).
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Figure 4. Forest plot of comparison: transient dyspnoea index.
Cough-free days
A significant difference between groups was reported for cough-
free days; those in the combined ICS-LABA group had 15.3% of
days cough-free compared with 3% in the ICS group (MD 12.30,
95% CI 2.38 to 22.2; Analysis 1.3, Figure 5).
Figure 5. Forest plot of comparison: cough-free days.
Exacerbations
No significant difference in the number of participants who expe-
rienced exacerbations was reported (seven in the ICS group and
four in the ICS-LABA group). No significant differences in hospi-
talisation were described between groups (OR 0.26, 95% CI 0.02
to 2.79; Analysis 1.4, Figure 6). We did not include exacerbations
in a forest plot because it was not mentioned in the study whether
seven and four participants, respectively, were having at least one
exacerbation, or whether few participants experienced more than
one exacerbation.
Figure 6. Forest plot of comparison: exacerbations.
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Secondary outcomes
The single included study reported the results for other secondary
outcomes including lung function and proportions of participants
experiencing adverse effects of the intervention. Investigators did
not use change in radiology scores as an outcome, and no deaths
were reported in the trial period. Relevant inflammatory markers
for the airway were not tested.
Lung function
No significant change in lung function indices was reported in
the sole included study. Although FEV1 seemed to improve more
in the high-dose budesonide group (MD -14.00, 95% CI -86.83
to 58.83; Analysis 1.5, Figure 7) and forced vital capacity (FVC)
improved more in the combination group (MD 14.00, 95% CI -
63.17 to 91.17; Analysis 1.6), the differences were not significant
.
Figure 7. Forest plot of comparison: FEV1 (change from baseline in mL).
Adverse events
Study authors reported a significant difference in the number of
adverse events, with the ICS group experiencingmore events. They
described 37 adverse events in the ICS group versus 12 events in the
ICS-LABA group but did not mention the number of individuals
who experienced adverse events.
D I S C U S S I O N
This review included data from only one study, and the results of
the review are different from those reported in the study, as the
study authors had described the study as double-blinded when
it was not, and the difference in QOL between the two groups
was not significant, as was stated in the study. We found that the
LABA-ICS group had significantly better control of bronchiecta-
sis in terms of cough-free days and transitional dyspnoea index,
but no significant difference between groups could be found for
QOL (as measured by SGRQ), lung function, number of partic-
ipants with one or more exacerbations or adverse events. Given
the high risk of bias and the small number of participants in the
single included study, widespread applicability of these results is
substantially limited.
This review summarises the best evidence available up to Septem-
ber 2013 and emphasises the paucity of trials testing the combina-
tion of LABA with ICS for bronchiectasis in adults and children.
Summary of main results
This review is limited to a single study eligible for inclusion
(Martinez-Garcia 2012). The combination of LABA-ICS was
marginally better than high-dose ICS in improving only a few
clinical indices of bronchiectasis symptom control in adults with
stable state non-CF bronchiectasis without co-existent asthma. Al-
though the study has been reported as a double-blinded trial, we
assessed it as having high risk of blinding and performance bias, as
well as detection bias, as the two inhalers were of different colours
therefore quality of evidence across the outcomes from the study
were downgraded to low quality evidence. There were no studies
in support or otherwise for the ICS-LABA combination for non-
CF bronchiectasis in children or adults with acute exacerbations.
Overall the quality of evidence based on this review is low, and
conclusions are likely to change as more evidence becomes avail-
able.
Overall completeness and applicability of
evidence
Although this review provides some evidence of possible benefit
derived from using combined LABA-ICS rather than high-dose
inhaled steroids in patients with non-CFbronchiectasis, the results
from a single study on clinical efficacy and safety of budesonide-
formoterol over three months cannot be applied to all LABA and
ICS combinations. This review highlights the fact that there re-
mains a paucity of high-quality data to support the routine use
of combined ICS-LABA. We need more robust evidence for the
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use of combination LABA-ICS in stable and exacerbation states
of non-CF bronchiectasis.
The reason why we cannot make any significant recommendations
based on the results of this review are manifold: First, this review
is based on a single study in adults, and no studies in children
have been identified. Second, no studies were identified for use of
the LABA-ICS combination for acute exacerbations. Third, the
number of participants (20 in each group) and the duration of
follow-up (three months) were small. Fourth, the sole included
study has a high risk of bias. Last, even though the study authors
excluded participants with asthma and COPD, participants were
not tested for airway hyperreactivity, and this could be a reason
for the non-significant difference between the two groups.
With no paediatric trial available at the time of this review, extrap-
olation of results to children cannot be recommended. As this was
a single-study review, it was not possible to examine whether the
duration of the intervention affected the findings.
Quality of the evidence
Only a single study was included in this review, hence the quality
of evidence is substantially limited.
Potential biases in the review process
The Cochrane Airways Group conducted an extensive search for
RCTs in children and adults with bronchiectasis. Two review au-
thors independently screened the searches and identified one study
for inclusion. We identified the sole included study itself as having
overall high risk of bias. We contacted the original investigators,
who kindly provided additional information about randomisation
and blinding.
Agreements and disagreements with other
studies or reviews
Evidence shows that a proportion of patients with bronchiecta-
sis have increased airway hyperreactivity (Müsellim 2013; Pang
1989), and in adults with bronchiectasis, bronchodilator use is as-
sociatedwith greater decline in lung functionover two-year follow-
up (King 2005). Further, the ICS-LABA combination has proved
better than ICS alone in asthma and COPD (Chroinin 2009;
Nannini 2013). These results have been extrapolated to adults and
children with bronchiectasis for use of a combination of ICS with
LABA, but evidence to support it is lacking.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Results of a small single trial at high risk of bias suggest that LABA
combined with ICS (compared with high-dose ICS) may be ben-
eficial in adult patients with stable bronchiectasis without co-ex-
istent asthma in improving symptom control. However, in the
absence of sufficient evidence, combined ICS-LABA cannot be
routinely recommended for adults or children with bronchiecta-
sis. Until further evidence becomes available, we recommend that
therapy be individualised on the basis of the presence or absence of
co-existing airway hyperresponsiveness and consideration of ad-
verse events associated with combined ICS-LABA.
Implications for research
This review highlights the fact that we need large RCTs compar-
ing the combination of inhaled LABA with ICS versus placebo
or ICS in adults and children in stable and exacerbation states of
bronchiectasis. Future RCTs should consider the following fea-
tures.
• Double-blind, randomised, parallel studies.
• Inclusion of placebo and inhaled steroids alone.
• In the case of different coloured inhalers, a double-dummy
trial.
• Minimal intervention period of six to 12 months to
account for the long-term adverse effects of steroids.
• Clearly defined outcome measures, including validated
QOL indices and changes in lung function, sputum volume,
microbiology data and sputum and/or blood inflammatory
markers.
• A priori definition of bronchial hyperreactivity with a
planned subgroup analysis in participants with hyperreactivity.
• Powered to enable treatment stratification (co-existent
asthma vs overall effect).
• Complete reporting of continuous (N, mean change and
mean standard deviation of change) and dichotomous
(denominators and event rate) data.
• Protocol-defined exacerbations and adverse events and data
presented as numbers of participants as well as numbers of events.
• Well-defined adverse events, including pharyngeal
candidiasis, voice change, adrenal suppression, osteopenia, effect
on linear growth etc.
• Stratification based on causes of bronchiectasis and the
presence or absence of Pseudomonas aeruginosa.
• Use of ITT analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Martinez-Garcia 2012
Methods Randomised, non-blinded, parallel-group clinical trial from a single centre: La Fe Uni-
versity Hospital, Valencia, Spain
3 -month run-in period followed by 3 months of intervention.
2 withdrawals in ICS because of adverse events; 1 in the LABA-ICS group did not return
Participants 40 participants between 18 and 80 years of age with non-CF bronchiectasis
1. Mean age 70.1 years
2. 45% male participants
3. Mean smoking history of 4.7 pack-years with no differences between the 2 groups
4. Baseline lung function FEV1 1297 mL (61% of predicted) with no differences
between groups
Diagnosis of bronchiectasis established by chest high-resolution CT (HRCT) scan per-
formed a maximum of 12 months before the start of the study
Inclusion criteria
1. Known chronic airflow obstruction
2. Clinically stable phase (i.e. free from acute exacerbation for at least 6 weeks)
Exclusion criteria
1. Cigarette smoking history of 10 pack-years
2. Occupational risk for COPD
3. Long-term oral steroid treatment
4. Traction bronchiectasis due to advanced fibrosis
5. Known intolerance for ICS or LABA
6. Asthma
7. Cardiopulmonary conditions that could modify spirometric values or its course
Interventions Interventions
During the first stage (run-in period):
All participants received 3-month high-dose budesonide dipropionate (1600microgram)
treatment
In the second stage, participants were randomly assigned to either
1. Continuing high-dose budesonide dipropionate (1600 microgram) treatment
dosed in two inhalations every 12 hours, or
2. A single Turbuhaler inhaler with half of the budesonide daily dose and formoterol
(18 micrograms of formoterol furoate and 640 micrograms of budesonide
dipropionate), dosed in 2 inhalations every 12 hours
Outcomes Clinical and health-related quality of life (HRQOL) measures at randomisation and at
3 months
Pulmonary function at randomisation and at 3 months
Microbiologic data at randomisation and at 3 months
Exacerbations
Notes
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Martinez-Garcia 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence was generated by a com-
puter, but details were not provided
Allocation concealment (selection bias) Unclear risk Not mentioned in the study, although the
drug was dispensed by an independent
pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The 2 inhalers were different in colour,
hence we judged that the participants
were not blinded (although the manuscript
mentioned it was a double-blinded study).
These data were obtained from the primary
author of the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Primary outcome (mentioned in trial reg-
istration but not in paper) was St George’s
Respiratory Questionnaire (SGRQ) at 3
months and at 6 months. As participants
were not blinded, risk of detection bias was
high
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants withdrawing from each group
accounted for and final intention-to-treat
analysis used
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Study partially sponsored by a company
with pharmaceutical interest
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ding 2006 Article in Chinese; a study of 34 participants compared 3 groups given routine care (n = 11) vs nebulised
terbutaline (n = 11) vs terbutaline + budesonide (n = 12). Excluded, as terbutaline is not a LABA
Mostafapour 2009 Excluded because this was a non-randomised study; all 12 participants recruited into the study were given the
study medication
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D A T A A N D A N A L Y S E S
Comparison 1. Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life (change in total
SGRQ score from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Transition dyspnoea index
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Cough-free days (percentage) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Hospitalisations 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 FEV1 (change from baseline in
mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 FVC (change from baseline in
mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 1 Quality of life (change in total SGRQ score from baseline).
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 1 Quality of life (change in total SGRQ score from baseline)
Study or subgroup ICS-LABA ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Martinez-Garcia 2012 20 -5.3 (12.6) 20 -0.73 (12.6) -4.57 [ -12.38, 3.24 ]
-100 -50 0 50 100
Favours ICS-LABA Favours ICS
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Analysis 1.2. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 2 Transition dyspnoea index (change from baseline).
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 2 Transition dyspnoea index (change from baseline)
Study or subgroup ICS-LABA ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Martinez-Garcia 2012 20 1.39 (1.44) 20 0.1 (1.44) 1.29 [ 0.40, 2.18 ]
-4 -2 0 2 4
Favours ICS Favours ICS-LABA
Analysis 1.3. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 3 Cough-free days (percentage).
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 3 Cough-free days (percentage)
Study or subgroup ICS-LABA ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Martinez-Garcia 2012 20 15.3 (16.01) 20 3 (16.01) 12.30 [ 2.38, 22.22 ]
-100 -50 0 50 100
Favours ICS Favours ICS-LABA
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Analysis 1.4. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 4 Hospitalisations.
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 4 Hospitalisations
Study or subgroup ICS-LABA ICS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinez-Garcia 2012 1/20 3/18 0.26 [ 0.02, 2.79 ]
0.01 0.1 1 10 100
Favours ICS-LABA Favours ICS
Analysis 1.5. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 5 FEV1 (change from baseline in mL).
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 5 FEV1 (change from baseline in mL)
Study or subgroup ICS-LABA ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Martinez-Garcia 2012 20 23 (103.62) 20 37 (121.96) -14.00 [ -84.14, 56.14 ]
-100 -50 0 50 100
Favours ICS-LABA Favours ICS
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Analysis 1.6. Comparison 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis
control, Outcome 6 FVC (change from baseline in mL).
Review: Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis
Comparison: 1 Combined ICS-LABA vs high-dose ICS; clinical indices of bronchiectasis control
Outcome: 6 FVC (change from baseline in mL)
Study or subgroup ICS-LABA ICS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Martinez-Garcia 2012 20 74 (128.2) 20 60 (120.7) 14.00 [ -63.17, 91.17 ]
-100 -50 0 50 100
Favours ICS-LABA Favours ICS
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (The Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and the RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Terms used in plain language summary
Scientific Term Plain language
Bronchiectasis Refers to dilatation of bronchi (breathing tubes) identified on CT scan of chest in the presence of relevant
clinical features
Exacerbation Flare-up, worsening of symptoms of cough, shortness of breath, etc
Indices of clinical stability Clinical signs pointing to stability of the disease
Dyspnoea Shortness of breath
Bronchial hyperreactivity Inappropriate reaction of the airway smooth muscle to different stimuli
Placebo Simulated or otherwise medically ineffectual treatment
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by both review authors on the basis of previous protocols on bronchiectasis (Kapur 2009). VG and AC
selected articles from the search, analysed the data independently and wrote the manuscript. VG contacted the authors of the included
study to ask for further information.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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